Tagged with STrategy

Turkey Muzaffer Bal, CEO of Ali Raif, a Turkish generics firm, highlights the company’s new investment in a manufacturing plant, their refusal to follow the trend of Turkish local companies investing in biosimilars, and how the current pricing system is putting the sustainability of the Turkish pharma industry in danger.  …

Singapore Industry veteran Marine Queniart-Stojanovic, a self-described “global citizen with a French passport,” currently serves as Sanofi’s GM for general medicines in Thailand, Malaysia, and Singapore. With Sanofi undergoing a significant transformation in its business approach, Queniart-Stojanovic is adapting this to the market realities in her managed countries as well as…

Turkey Ilko Pharmaceuticals is a family-owned Turkish generics and biosimilars company. General Manager Hatice Öncel explains the company’s investment in biosimilars in collaboration with South Korea’s Genexine and how recent success in consumer health has allowed them to overperform the local market with 27 percent growth in 2020. In addition, she…

Turkey İsmail  Yormaz, Recordati’s VP and regional director for south-east, highlights how the Milan-based company has become a shining example of a successful localization strategy, upcoming launches and investments, as well as some of the challenges that the firm is facing in Turkey, including the country’s challenging pricing system.   The…

Singapore Industry veteran Marine Queniart-Stojanovic outlines the significance of the Thailand-Malaysia-Singapore country grouping to Sanofi’s APAC operations; how the company’s global rationalisation and prioritisation push has been reflected at the country level; and why inter-stakeholder collaboration will be crucial to developing patient-centric solutions in a post-pandemic world.   I always come…

Turkey Takeda’s general manager for Turkey, Şeyda Atadan Memiş, reflects on the Japanese giant’s ambitions in Turkey at a pivotal moment when the Shire integration has been completed. Atadan discusses how the organization has seized on Takeda’s revamped portfolio, focusing on rare diseases, haematology, immunology, gastroenterology, and oncology, to move up…

Singapore Erika Pagani, country manager for Pfizer Singapore, shares her journey with the company from Brazil to New York, Peru, Ecuador, and finally Singapore. She discusses why the island city-state is well-positioned as a launchpad for Pfizer’s innovation and the “laboratory” for emerging Asia, and how the company is working to…

Mexico During a year where the Mexican economy shrank 8.5 percent, Novartis Mexico experienced a modest one percent growth which Country President Fernando Cruz, qualified as “reasonably good” considering the impacts of COVID-19, down from 4.5 percent growth in 2019.   “In summary, our strategy for 2021 is to be aggressive…

Turkey After an international career spanning 25 years, Demet Russ returned to her native Turkey to lead the Janssen affiliate during a tumultuous time and is aiming to give back to her country by improving patients’ access to life-saving therapies.   For Russ, what began as a consultant role at McKinsey…

Saudi Arabia Dr Fayad Al Dandashi, CEO of Tamer HealthCare, a leading Saudi healthcare company, discusses how the group aims to benefit from Saudi Arabia’s healthcare transformation through digitalization, changing their product-oriented business model to a holistic service-driven business model. After years of entrepreneurial and public sector experience, he explains the changes…

Saudi Arabia Hussein El Hakim, managing director for Bayer Saudi Arabia and general manager for its pharmaceuticals division in the country, discusses the affiliate’s rapid expansion after years of double-digit growth. El Hakim explains how the German Life Science company is approaching the transformation of the Saudi healthcare market, with changes in…

Turkey Avinash Potnis of Novartis Turkey discusses potential solutions to the country’s access and pricing dilemma which has raised concerns of system sustainability. Potnis also highlights the strengths of Turkey’s healthcare infrastructure, workforce, and the country’s prospects as a globally competitive innovation hub.   Turkey has a unique value proposition, bringing…